In one aspect, methods are described herein employing particle compositions operable to form composite membrane for inhibition of post-surgical adhesions. Briefly, a method of treating a surgical site comprises contacting the surgical site with a particle formulation comprising targeting particles and scaffolding particles. The targeting particles and scaffolding particles are crosslinked to provide a composite membrane at the surgical site, wherein formation of post-surgical adhesions are inhibited by the composite membrane.

The present disclosure provides methods for restoring reproductive health and/or fertility in a subject by delivering immature follicles to the subject using an ovarian-derived hydrogel. The present disclosure also provides methods for treating ovarian-associated diseases using ovarian-derived hydrogels or their derivatives for delivery of therapeutic agents to the subject in need thereof. The present disclosure further provides kits for restoring reproductive health and/or fertility, and kits for treating ovarian-associated diseases.

An implantation needle for inserting a subcutaneously insertable element into a body tissue, a kit for inserting a subcutaneously insertable element into a body tissue and a method of manufacturing an implantation needle are described. The implantation needle comprises at least one covering comprising at least one pharmaceutical compound. The pharmaceutical compound is configured to remain at least partially in the body tissue after insertion of the subcutaneously insertable element.

The present disclosure provides an ophthalmic article. The ophthalmic article may comprise a biocompatible matrix comprising a copolymer derived from a caprolactone monomer and at least one other monomer. The ophthalmic article may also comprise an active agent or a diagnostic agent. The ophthalmic article may be configured to associate to a haptic of an intraocular lens (IOL).

Disclosed herein are elastic, bioresorbable encasements for medical implants, methods for making the same and uses thereof.

The present invention provides, in some aspects, bilayered and trilayered pharmaceutical implant compositions for the unidirectional delivery of anti-cancer compounds to the brain over a period of time (e.g., several weeks, 1, 2, 3, 4, 5, 6, 7 days, or 1, 2, 3, weeks, or any range derivable therein) following the removal of glioblastoma multiforme or other malignant tumors in the brain.

The present invention provides, in some aspects, bilayered and trilayered pharmaceutical implant compositions for the unidirectional delivery of anti-cancer compounds to the brain over a period of time (e.g., several weeks, 1, 2, 3, 4, 5, 6, 7 days, or 1, 2, 3, weeks, or any range derivable therein) following the removal of glioblastoma multiforme or other malignant tumors in the brain.

In some embodiments, the present invention provides methods for making resorbable ear tubes including the steps of providing a silk fibroin solution, and forming a silk ear tube from the silk fibroin solution, wherein the silk ear tube is less than 2 mm in length and has an outer diameter of less than 1.5 mm, and wherein the silk ear tube is resorbable. In some embodiments, the present invention also provides methods for treating otitis media including the step of introducing a silk ear tube into the ear canal of a subject, wherein the silk ear tube is less than 2 mm in length and has an outer diameter of less than 1.5 mm, and wherein the silk ear tube is resorbed by the subject.

When transplanting a plurality of ovarian tissue fragments, agglomeration of ovarian tissue fragments is prevented, angiogenesis is promoted, and engraftment rate is improved. When transplanting a plurality of ovarian tissue fragments formed by cutting ovarian tissue into a mammal, and the ovarian tissue fragments are transplanted by an injection step in which collagen gel is injected into a site to be transplanted, using collagen gel with a gel concentration of about 1%, and then a transplantation step in which the plurality of ovarian tissue fragments are inserted into the collagen gel. At this time, each of the plurality of ovarian tissue fragments may be previously encapsulated with the collagen gel.

A reservoir device comprising an active agent formulation contained within a reservoir is described. The reservoir is defined by a biodegradable, permeable polymer membrane having a thickness of at least 45 μm. The membrane allows for diffusion of an active agent of the formulation there through when positioned subcutaneously in a body of a subject.